inovio pharmaceuticals - INO
INO
Close Chg Chg %
1.76 -0.03 -1.70%
Closed Market
1.73
-0.03 (1.70%)
Volume: 634.16K
Last Updated:
Mar 28, 2025, 4:00 PM EDT
Company Overview: inovio pharmaceuticals - INO
INO Key Data
| Open $1.76 | Day Range 1.68 - 1.77 |
| 52 Week Range 1.68 - 14.75 | Market Cap $64.53M |
| Shares Outstanding 36.67M | Public Float 36.41M |
| Beta 0.92 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$3.98 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 702.70K |
INO Performance
| 1 Week | -9.90% | ||
| 1 Month | -12.63% | ||
| 3 Months | -7.49% | ||
| 1 Year | -87.54% | ||
| 5 Years | -98.27% |
INO Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
6
Full Ratings ➔
About inovio pharmaceuticals - INO
Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.
INO At a Glance
Inovio Pharmaceuticals, Inc.
660 West Germantown Pike
Plymouth Meeting, Pennsylvania 19462-1111
| Phone | 1-267-440-4200 | Revenue | 217.76K | |
| Industry | Pharmaceuticals: Major | Net Income | -107,254,126.00 | |
| Sector | Health Technology | Employees | 134 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
INO Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 228.257 |
| Price to Book Ratio | 0.964 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.294 |
| Enterprise Value to Sales | -149.452 |
| Total Debt to Enterprise Value | -0.365 |
INO Efficiency
| Revenue/Employee | 1,625.045 |
| Income Per Employee | -800,403.925 |
| Receivables Turnover | 0.182 |
| Total Asset Turnover | 0.002 |
INO Liquidity
| Current Ratio | 2.769 |
| Quick Ratio | 2.769 |
| Cash Ratio | 2.664 |
INO Profitability
| Gross Margin | -1,337.408 |
| Operating Margin | -52,351.678 |
| Pretax Margin | -49,254.269 |
| Net Margin | -49,254.269 |
| Return on Assets | -74.522 |
| Return on Equity | -115.418 |
| Return on Total Capital | -133.452 |
| Return on Invested Capital | -104.003 |
INO Capital Structure
| Total Debt to Total Equity | 17.32 |
| Total Debt to Total Capital | 14.763 |
| Total Debt to Total Assets | 10.326 |
| Long-Term Debt to Equity | 13.675 |
| Long-Term Debt to Total Capital | 11.656 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Inovio Pharmaceuticals - INO
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 1.77M | 10.26M | 832.01K | 217.76K | |
Sales Growth
| -76.05% | +478.23% | -91.89% | -73.83% | |
Cost of Goods Sold (COGS) incl D&A
| 4.73M | 5.50M | 3.50M | 3.13M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 4.73M | 5.50M | 3.50M | 3.13M | |
Depreciation
| 4.21M | 5.00M | 3.36M | 3.13M | |
Amortization of Intangibles
| - | 520.41K | 496.49K | 145.42K | |
COGS Growth
| - | +16.18% | -36.25% | -10.66% | |
Gross Income
| (2.96M) | 4.77M | (2.67M) | (2.91M) | |
Gross Income Growth
| - | +261.24% | -156.05% | -9.01% | |
Gross Profit Margin
| -166.56% | +46.44% | -321.09% | -1,337.41% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 308.26M | 279.04M | 132.56M | 111.09M | |
Research & Development
| 259.24M | 194.35M | 88.48M | 77.22M | |
Other SG&A
| 49.02M | 84.69M | 44.08M | 33.87M | |
SGA Growth
| +131.31% | -9.48% | -52.50% | -16.20% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 3.22M | 7.85M | 4.66M | (4.89M) | |
EBIT after Unusual Expense
| (314.44M) | (282.12M) | (139.89M) | (109.11M) | |
Non Operating Income/Expense
| 13.15M | 5.72M | 5.99M | 2.04M | |
Non-Operating Interest Income
| 3.36M | 4.78M | 8.13M | 4.77M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 1.94M | 1.25M | 1.22M | 177.83K | |
Interest Expense Growth
| -77.75% | -35.24% | -2.49% | -85.46% | |
Gross Interest Expense
| 1.94M | 1.25M | 1.22M | 177.83K | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (303.22M) | (277.65M) | (135.12M) | (107.25M) | |
Pretax Income Growth
| -86.15% | +8.43% | +51.34% | +20.62% | |
Pretax Margin
| -17,085.39% | -2,705.57% | -16,239.87% | -49,254.27% | |
Income Tax
| - | - | - | - | - |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (303.66M) | (279.82M) | (135.12M) | (107.25M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (303.66M) | (279.82M) | (135.12M) | (107.25M) | |
Net Income Growth
| -82.47% | +7.85% | +51.71% | +20.62% | |
Net Margin Growth
| -17,109.87% | -2,726.67% | -16,239.87% | -49,254.27% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (303.66M) | (279.82M) | (135.12M) | (107.25M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (303.66M) | (279.82M) | (135.12M) | (107.25M) | |
EPS (Basic)
| -17.4492 | -14.0717 | -6.0936 | -3.9488 | |
EPS (Basic) Growth
| -35.55% | +19.36% | +56.70% | +35.20% | |
Basic Shares Outstanding
| 17.40M | 19.89M | 22.17M | 27.16M | |
EPS (Diluted)
| -17.4492 | -14.0717 | -6.0936 | -3.9488 | |
EPS (Diluted) Growth
| -35.55% | +19.36% | +56.70% | +35.20% | |
Diluted Shares Outstanding
| 17.40M | 19.89M | 22.17M | 27.16M | |
EBITDA
| (306.49M) | (268.78M) | (131.72M) | (110.87M) | |
EBITDA Growth
| -143.53% | +12.30% | +50.99% | +15.83% | |
EBITDA Margin
| -17,269.24% | -2,619.08% | -15,831.92% | -50,914.27% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 7.833 | |
| Number of Ratings | 6 | Current Quarters Estimate | -0.692 | |
| FY Report Date | 03 / 2025 | Current Year's Estimate | -2.587 | |
| Last Quarter’s Earnings | -0.65 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -3.95 | Next Fiscal Year Estimate | -2.227 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 5 | 5 | 6 | 5 |
| Mean Estimate | -0.69 | -0.65 | -2.59 | -2.23 |
| High Estimates | -0.50 | -0.50 | -0.96 | -0.55 |
| Low Estimate | -0.84 | -0.85 | -4.45 | -3.41 |
| Coefficient of Variance | -18.38 | -21.74 | -44.62 | -55.48 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 3 | 3 | 3 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 3 | 3 | 3 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Inovio Pharmaceuticals - INO
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Inovio Pharmaceuticals - INO
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Mar 3, 2025 | Peter D. Kies CFO | 31,012 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 3, 2025 | Laurent M. Humeau Chief Scientific Officer | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 3, 2025 | Laurent M. Humeau Chief Scientific Officer | 29,559 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $1.98 per share | 58,526.82 |
| Mar 3, 2025 | Laurent M. Humeau Chief Scientific Officer | 31,618 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 3, 2025 | Laurent M. Humeau Chief Scientific Officer | 26,608 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $1.98 per share | 52,683.84 |
| Mar 3, 2025 | Laurent M. Humeau Chief Scientific Officer | 28,192 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 3, 2025 | Peter D. Kies CFO | 31,900 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 3, 2025 | Peter D. Kies CFO | 39,050 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 3, 2025 | Peter D. Kies CFO | 10,019 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 3, 2025 | Peter D. Kies CFO | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 3, 2025 | Peter D. Kies CFO | 28,052 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $1.98 per share | 55,542.96 |
| Mar 3, 2025 | Michael Sumner Chief Medical Officer | 13,229 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 3, 2025 | Peter D. Kies CFO | 26,002 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $1.98 per share | 51,483.96 |
| Mar 3, 2025 | Peter D. Kies CFO | 28,364 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 3, 2025 | Laurent M. Humeau Chief Scientific Officer | 10,019 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 3, 2025 | Laurent M. Humeau Chief Scientific Officer | 27,402 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 3, 2025 | Michael Sumner Chief Medical Officer | 42,900 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 3, 2025 | Laurent M. Humeau Chief Scientific Officer | 22,098 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 3, 2025 | Michael Sumner Chief Medical Officer | 10,019 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 3, 2025 | Michael Sumner Chief Medical Officer | 34,650 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |